Fast In-House Next-Generation Sequencing in the Diagnosis of Metastatic Non-small Cell Lung Cancer: A Hospital Budget Impact Analysis

被引:0
|
作者
Silas, Ubong [1 ]
Blueher, Maximilian [1 ]
Smith, Antonia Bosworth [1 ]
Saunders, Rhodri [1 ]
机构
[1] Coreva Sci GmbH & Co KG, Konigswinter, Germany
来源
关键词
targeted therapy; turnaround time; health economic analysis; hospital costs; genetic testing; return on investment;
D O I
10.36469/jheor.2023.77686
中图分类号
F [经济];
学科分类号
02 ;
摘要
Background: Targeted therapy for cancer is becoming more frequent as the understanding of the molecular pathogenesis increases. Molecular testing must be done to use targeted therapy. Unfortunately, the testing turnaround time can delay the initiation of targeted therapy. Objective: To investigate the impact of a next-generation sequencing (NGS) machine in the hospital that would allow for in-house NGS testing of metastatic non-small cell lung cancer (mNSCLC) in a US setting. Methods: The differences between 2 hospital pathways were established with a cohort-level decision tree that feeds into a Markov model. A pathway that used in-house NGS (75%) and the use of external laboratories (so-called send-out NGS) (25%), was compared with the standard of exclusively send-out NGS. The model was from the perspective of a US hospital over a 5-year time horizon. All cost input data were in or inflated to 2021 USD. Scenario analysis was done on key variables. Results: In a hospital with 500 mNSCLC patients, the implementation of in-house NGS was estimated to increase the testing costs and the revenue of the hospital. The model predicted a $710 060 increase in testing costs, a $1 732 506 increase in revenue, and a $1 022 446 return on investment over 5 years. The payback period was 15 months with in-house NGS. The number of patients on targeted therapy increased by 3.38%, and the average turnaround time decreased by 10 days when in-house NGS was used. Discussion: Reducing testing turnaround time is a benefit of in-house NGS. It could contribute to fewer mNSCLC patients lost to second opinion and an increased number of patients on targeted therapy. The model outcomes predicted that, over a 5-year period, there would be a positive return on investment for a US hospital. The model reflects a proposed scenario. The heterogeneity of hospital inputs and the cost of send-out NGS means context-specific inputs are needed. Conclusion: Using in-house NGS testing could reduce the testing turnaround time and increase the number of patients on targeted therapy. Additional benefits for the hospital are that fewer patients will be lost to second opinion and that in-house NGS could generate additional revenue.
引用
收藏
页码:111 / 118
页数:8
相关论文
共 50 条
  • [41] Secondary myelodysplastic syndromes identified via next-generation sequencing in a non-small cell lung cancer patient
    Yongzhi Feng
    Xialin Chen
    Keran Jiang
    Ding Zhang
    Feng Tao
    Dan Ni
    Jun Zhang
    Lixin Wu
    Jinping Cai
    Libin Jiang
    GenHua Yu
    Lin Shi
    BMC Medical Genomics, 14
  • [42] Relevance of Next-Generation Sequencing in Non-Small Cell Lung Cancer; Molecular Epidemiology Study in Indian Patients
    Aggarwal, Aditi
    Sabnis, Neha
    Mishra, Avshesh
    Kumar, Vipin
    Mohanty, Sagar Samrat
    Kini, Lata
    Sharma, Shivani
    Mohanty, Sambit
    LABORATORY INVESTIGATION, 2021, 101 (SUPPL 1) : 1087 - 1088
  • [43] The rational application of liquid biopsy based on next-generation sequencing in advanced non-small cell lung cancer
    Zhao, Chenglong
    Li, Jianghua
    Zhang, Yongchang
    Han, Rui
    Wang, Yubo
    Li, Li
    Zhang, Yimin
    Zhu, Mengxiao
    Zheng, Jie
    Du, Haiwei
    Hu, Chen
    Zhou, Chengzhi
    Yang, Nong
    Cai, Shangli
    He, Yong
    CANCER MEDICINE, 2023, 12 (05): : 5603 - 5614
  • [44] The correlation between crizotinib efficacy and molecular heterogeneity by next-generation sequencing in non-small cell lung cancer
    Lv, Tangfeng
    Zou, Qian
    Song, Zhengbo
    Liu, Hongbing
    Wang, Qiming
    Song, Yong
    JOURNAL OF THORACIC DISEASE, 2018, 10 (05) : 2948 - +
  • [45] Relevance of Next-Generation Sequencing in Non-Small Cell Lung Cancer; Molecular Epidemiology Study in Indian Patients
    Aggarwal, Aditi
    Sabnis, Neha
    Mishra, Avshesh
    Kumar, Vipin
    Mohanty, Sagar Samrat
    Kini, Lata
    Sharma, Shivani
    Mohanty, Sambit
    MODERN PATHOLOGY, 2021, 34 (SUPPL 2) : 1087 - 1088
  • [46] A Pathology Group Experience with Targeted Next-Generation Sequencing (NGS) for Non-Small Cell Lung Cancer (NSCLC)
    Xu, D.
    Zhang, M.
    Keenan, S. O.
    Coleman, R.
    Tevis, A. Larson
    Rushford, C.
    Christensen, T.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2019, 21 (06): : 1226 - 1226
  • [47] A novel RET fusion in non-small cell lung cancer identified by next-generation sequencing: a case report
    Xu, Xiaoyi
    Wang, Haoyi
    Yu, Zhaonan
    Chen, Xianguo
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2022, 148 (07) : 1825 - 1827
  • [48] Concordance of next-generation sequencing between tissue and liquid biopsies in non-small cell lung cancer.
    Basher, Fahmin
    Saravia, Diana
    Fanfan, Dino
    Cotta, Jared Addison
    Lopes, Gilberto
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [49] The correlation between Crizotinib efficacy and molecular heterogeneity by next-generation sequencing in non-small cell lung cancer
    Lv, Tangfeng
    Song, Yong
    Zou, Qian
    Song, Zhengbo
    Liu, Hongbing
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [50] Costs of Next-Generation Sequencing Assays in Non-Small Cell Lung Cancer: A Micro-Costing Study
    Kumar, Srishti
    Bennett, Alexandria
    Campbell, Pearl A.
    Palidwor, Gareth
    Lo, Bryan
    Perkins, Theodore J.
    Nochaiwong, Surapon
    Sekhon, Harmanjatinder S.
    Stewart, David J.
    Thavorn, Kednapa
    CURRENT ONCOLOGY, 2022, 29 (08) : 5238 - 5246